|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Veno occlusive disease: Update on clinical management显示文摘Hepatic veno-occlusive disease is a clinical syndrome characterized by hepatomegaly, ascites, weight gain and jaundice, due to sinusoidal congestion which can be caused by alkaloid ingestion, but the most frequent cause is haematopoietic stem cell transplantation (STC) and is also seen after solid organ transplantation. The incidence of veno occlusive disease (VOD) after STC ranges from 0 to 70%, but is decreasing. Survival is good when VOD is a mild form, but when it is severe and associated with an increase of hepatic venous pressure gradient > 20 mmHg, and mortality is about 90%. Prevention remains the best therapeutic strategy, by using non-myeloablative conditioning regimens before STC. Prophylactic administration of ursodeoxycholic acid, being an antioxidant and antiapoptotic agent, can have some benefit in reducing overall mortality. Defibrotide, which has pro-fibrinolytic and antithrombotic properties, is the most effective therapy; decompression of the sinusoids by a transjugular intrahepatic portosystemic shunt (TIPS) can be tried, especially to treat VOD after liver transplantation and when multiorgan failure (MOF) is not present. Liver transplantation can be the last option, but can not be considered a standard rescue therapy, because usually the concomitant presence of multiorgan failure contraindicates this procedure. | M Senzolo G Germani E Cholongitas P Burra AK Burroughs | 2007 | World Journal of Gastroenterology2007，13，29： | 19 |
| 2 | New insights into the coagulopathy of liver disease and liver transplantation显示文摘The liver is an essential player in the pathway of coagulation in both primary and secondary haemostasis. Only von Willebrand factor is not synthetised by the liver, thus liver failure is associated with impairment of coagulation. However, recently it has been shown that the delicate balance between pro and antithrombotic factors synthetised by the liver might be reset to a lower level in patients with chronic liver disease. Therefore, these patients might not be really anticoagulated in stable condition and bleeding may be caused only when additional factors, such as infections, supervene. Portal hypertension plays an important role in coagulopathy in liver disease, reducing the number of circulating platelets, but platelet function and secretion of thrombopoietin have been also shown to be impaired in patients with liver disease. Vitamin K deficiency may coexist, so that abnormal clotting factors are produced due to lack of gamma carboxylation. Moreover during liver failure, there is a reduced capacity to clear activated haemostatic proteins and protein inhibitor complexes from the circulation. Usually therapy for coagulation disorders in liver disease is needed only during bleeding or before invasive procedures. When end stage liver disease occurs, liver transplantation is the only treatment available, which can restore normal haemostasis, and correct genetic clotting defects, such as haemophilia or factor V Leiden mutation. During liver transplantation haemorrage may occur due to the pre-existing hypocoagulable state, the collateral circulation caused by portal hypertension and increased fibrinolysis which occurs during this surgery. | M Senzolo P Burra E Cholongitas AK Burroughs | 2006 | World Journal of Gastroenterology2006，12，48： | 12 |
| 3 | Transjugular int rahepatic portosystemic shunt for portal vein t hrombosis with and without cavernous transformation显示文摘 | Senzolo M Tibbals J Cholongitas E | 2006 | Aliment Pharmacol Ther2006，23，6： | 1 |
| 4 | Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options 显示文摘 | Papatheodoridis G V Cholongitas E | 2004 | J Viral Hepat2004，11，4： | 1 |
| 5 | Severe venoocclusive disease after liver transplantation treated with transjugular intrahepatic portosystemic shunt显示文摘 | Senzolo M Patch D Cholongitas E | 2006 | Transplantation2006，82，1： | 1 |
| 6 | Non-invasive tests for liver fibrosis:encouraging or discouraging results显示文摘 | Burroughs AK Cholongitas E | 2007 | J Hepatol2007，46，5： | 1 |
| 7 | The effects of glycosaminoglycans on coagulation:a thromboelastographic study显示文摘 | Senzolo M Coppell J Cholongitas E | 2007 | Blood Coagul Fibrinolysis2007，18，3： | 1 |
| 8 | Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis显示文摘 | Cholongitas E Papatheodoridis GV Lahanas A | 2005 | Liver Intenational2005，25，： | 1 |
| 9 | Comparison of cys- tatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis 显示文摘 | Xirouchakis E Marelli L Cholongitas E | 2011 | Clin J Am Soc Nephro12011，5，1： | 1 |
| 10 | The effects of glyeosa- minoglycans on coagulation:a thromboelastographic study显示文摘 | Senzolo M Coppell J Cholongitas E | 2007 | Blood Coagul Fibrinol2007，18，3： | 1 |
| 11 | Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti- inflammatory drugs 显示文摘 | Papatheodoridis G V Papadelli D Cholongitas E | 2004 | Am J Med2004，116，9： | 1 |
| 12 | Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome显示文摘 | Senzolo M Cholongitas E Tibballs J | 2006 | Eur J Gastroenterol Hepatol2006，18，11： | 1 |
| 13 | Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation显示文摘 | Senzolo M Tibbals J Cholongitas E | 2006 | Aliment Pharmacol Ther2006，23，6： | 1 |
| 14 | Liver grafts from anti-hepatitis B core positive donors: a systematic review显示文摘 | Cholongitas E Papatheodoridis GV Burroughs AK | 2010 | J Hepatol2010，52，2： | 1 |
| 15 | Review article: renal function assessment in dirrhosis-difficulties and alternative meas-urements显示文摘 | Cholongitas E Shusang V Marelli L | 2007 | Aliment Pharmacol Ther2007，26，7： | 1 |
| 16 | Heparin like Effect in Liver Disease and Liver Transplantation显示文摘 | Senzolo M Cholongitas E Thalheimer U | | 0，，01： | 1 |
| 17 | Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation 显示文摘 | Senzolo M Tibbals J Cholongitas E | 2006 | Aliment Pharmaeol Ther2006，23，6： | 1 |
| 18 | RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit显示文摘 | Cholongitas E Calvaruso Senzolo M | 2009 | Journal of Gastroenterology & Hepatology2009，24，10： | 1 |
| 19 | Re- view article: the extra -skeletal effects of vitamin D in chronic hepatitis C infection显示文摘 | CHOLONGITAS E THEOCHARIDQU E GOULIS J | 2012 | Aliment Pharmacol Ther2012，35，6： | 1 |
| 20 | Spontaneous bacterial peritonitis in cirrhotic patients:is prophylactic propranolol therapy beneficial显示文摘 | CHOLONGITAS E PAPATHEODORIDIS GV MANESIS EK | 2006 | J Gastroenterol Hepatol2006，21，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员